Where is Amipharm located?

Amipharm is headquartered in Seongnam-si, South Korea.

Where does Amipharm rank among its competitors?

Amipharm ranks 143rd amongst 216 active competitors, of which 49 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Collplant, which secured $4M in Feb, 2026.

Who are the top competitors of Amipharm?

Amipharm's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Among them, Collplant secured the most recent funding round in February, 2026.

Amipharm - 2026 Company Profile, Team, Funding & Competitors

Amipharm is a funded company based in Seongnam-si (South Korea), founded in 2005. It operates as a Developer of therapeutics for fat reduction. The company has 216 active competitors, including 49 funded and 68 that have exited. Its top competitors include companies like Revance Therapeutics, Lineage Cell Therapeutics and Evolus.

Company Details

Developer of therapeutics for fat reduction. The company's lead candidate is AYP-101 is polyene phosphatidylcholine (PPC), which is extracted from soybeans at high purity and administered via subcutaneous injection to treat for reducing fat.

Website: amipharm.com
Email ID: *****@amipharm.com
Phone Number: +82 **********

Key Metrics

Founded Year

2005

Location

Seongnam-si, South Korea

Stage

Funding Raised

Investors

Korea Investment Holdings

Ranked

143^rd among 216 active competitors

Similar Companies

Revance Therapeutics & 282 more

View Amipharm's full profile

Amipharm is a funded company. Amipharm has 1 institutional investor.

View details of Amipharm's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amipharm include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Here is the list of Top 10 competitors of Amipharm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	66/100
3rd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	62/100
4th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
5th	CoolSculpting 2005, Pleasanton (United States), Public	Permanently eliminate treated fat with CoolSculpting, a non-surgical body contouring	-	Aisling Capital, Advanced Technology Ventures	60/100
6th	Galderma 1981, Zug (Switzerland), Public	Manufacturer of products to treat a range of dermatological conditions	-	ADIA, HarbourVest Partners & 2 others	60/100
7th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	60/100
8th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
9th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
10th	SkinMedica 1999, Carlsbad (United States), Acquired	Science-backed skincare delivering transformative results through cleansers, moisturizers, sunscreens, and targeted treatments	$94.2M	http://pseps.com/company/perseus-soros-biopharmaceutical-fund-lp, Aisling Capital ... & 10 others	59/100
143rd	Amipharm 2005, Seongnam-si (South Korea), Funding Raised	Developer of therapeutics for fat reduction	-	Korea Investment Holdings	25/100